S
oluble guanylyl cyclase (sGC), rhizobial O 2 -sensing FixL protein, and CooA transcription factor from Rhodospirillum rubrum constitute a unique family of hemoproteins that stand apart from the rest of the heme-containing proteins (1) . In contrast to various hemoproteins, which use the heme moiety as a catalyst in redox reactions (e.g., cytochrome P450 and NO synthases) or as an oxygen storage-transporting moiety (hemoglobin and myoglobin), the heme group of these enzymes seems to have a unique role of being receptors specific to various physiologically relevant gaseous activators such as NO for sGC (2) , O 2 for FixL (3) , and CO for CooA transcription factor (4) . Binding of gaseous effectors induces conformational changes in the protein, resulting in the transition to an activated state.
sGC [GTP pyrophosphate-lyase (cycling), EC 4.6.1.2] is a key enzyme in the NO͞cGMP-dependent pathway, which plays an important role in mammalian physiology. sGC-mediated increases in intracellular cGMP affect smooth muscle relaxation, platelet aggregation, leukocyte adhesion, cell proliferation and migration, neurotransmission, and other effects (5, 6) . Mammalian sGC is a heterodimeric protein composed of one ␣ subunit and one ␤ subunit (7) . Two isoforms for each subunit (␣ 1 , ␣ 2 , ␤ 1 , and ␤ 2 ) have been described, but only ubiquitously expressed heterodimer ␣ 1 ␤ 1 and placenta-specific heterodimer ␣ 2 ␤ 1 have been identified thus far in human tissues. Both subunits are required for a fully active sGC (8) , although a recent report suggests that the ␤ 2 homodimer possesses some residual catalytic activity (9) albeit only with nonphysiological concentrations of Mn 2ϩ ion. NO binds to a heme prosthetic group found in the native enzyme. sGC heterodimer contains only one ferrous pentacoordinated heme with the His-105 residue of the ␤ subunit acting as the axial ligand (10, 11) . The binding of NO to the heme results in stimulation of sGC activity (12) , which increases the activity of purified enzyme several hundred-fold (13) (14) (15) .
Various analyses of UV-visible (UV-Vis) (10, 14) , EPR (16) , and Raman (17, 18) spectra described to a great extent the transformation of the sGC heme prosthetic group after binding of NO. Binding of NO to heme Fe 2ϩ and the formation of nitrosyl heme result in the disruption of the axial coordinating bond and displacement of iron from the protoporphyrin plane. The kinetic and mechanistic aspects of these transformations are currently subjects of investigation and debate (19) (20) (21) (22) .
Although the connection between the formation of the nitrosyl heme and activation of cGMP synthesis by sGC is well documented and accepted, little is known about the mechanism coupling these two events. Current views of sGC structure define a hemecontaining regulatory domain, formed by N-terminal portions of both subunits, and a catalytic domain formed by the C-terminal half of both subunits (23) . It is postulated that NO binding induces changes in the regulatory domain (24, 25) that are transmitted through a yet-unknown mechanism to the catalytic site, which results in a significant increase in V max of the enzyme and some decrease in the K m for GTP substrate (15, 26, 27) .
Although the key role of heme in NO activation is undisputed, there is no clear understanding of the role of the heme group in basal inactivated enzyme. In this report we investigate the role of the heme moiety in the basal state of recombinantly expressed human sGC. We present biochemical data from the analysis of the wild-type enzyme and a constitutively active heme-deficient mutant suggesting that the heme moiety and the heme-coordinating bond have an inhibitory function. On the basis of our data we propose that the heme moiety keeps the regulatory domain in a ''restricted'' basal conformation. This restricted basal conformation could be released not only after binding the NO ligand to heme but also, to various degrees, by the chemical or genetic removal of the heme moiety from the regulatory domain, which allows the enzyme to achieve the ''activated'' conformation. mutant sGC were expressed in Sf9 cells as described (28) . Sf9 cells were lysed by sonication in buffer A [25 mM triethanolamine (TEA), pH 7.5͞10% glycerol͞4 mM MgCl 2 ͞5 mM DTT͞1 mM PMSF͞5 mg/ml each of pepstatin A, leupeptin, aprotinin, and chymostatin], and the 100,000 g of supernatant fraction was loaded on a 20-ml DEAE-Sepharose column. Lysate with mutant enzyme was prepared in the absence of DTT. After extensive washes, the enzyme was eluted with a linear 0-100% gradient of buffer B (25 mM TEA, pH 7.5͞10% glycerol͞500 mM NaCl). Yellow fractions containing sGC were purified further by nickel chromatography as described (15, 28) . To remove the imidazole present in sGC fractions collected after nickel chromatography, the sGC sample was loaded on a 2-ml Hi-Trap DEAE-Sepharose column (Amersham Pharmacia Biotech), washed with buffer A, and eluted with buffer A with 250 mM NaCl. The enzyme obtained at this stage (Ն95% purity) was used for experiments.
region of ␤
Assay of sGC Activity. Enzyme activity was assayed by formation of [ 32 P]cGMP from [␣- 32 P]GTP at 37°C as described (29) . The concentration of DMSO used as a vehicle for BAY41-2272 was not Ͼ0.1% and had no effect on sGC activity. Activity of CO-treated enzyme was measured in gas-tight vials by using CO-equilibrated reaction buffer.
UV-Vis Spectroscopy. All measurements were recorded with a dualbeam Cecil 9500 spectrophotometer at 25°C. To monitor the heme reconstitution, wild-type and mutant enzymes in 25 mM TEA, pH 7.5͞10% glycerol͞250 mM NaCl͞4 mM MgCl 2 were used. A 5 mM stock solution of hemin prepared in alkaline 50% ethanol was used to make a 350 M working solution in buffer A without DTT and protease inhibitors. Identical amounts of hemin (0.5-10 M final concentration) were added to both sample and reference cuvettes, and difference spectra were recorded between 320 and 700 nm.
To obtain heme-reconstituted ␣␤ Cys-105 enzyme, 1 ml of 4 M mutant enzyme was supplied with 8 M hemin, and unbound hemin was removed by filtration through a 5-ml Hi-Trap desalting column (Amersham Biosciences). To reduce the ferric heme moiety, several grains of dithionate or 5 mM DTT were added to reconstituted enzyme. To measure the effects of NO, 50 M 3-(2-hydroxyl-1-methyl-2-nitrosohydrazino)-N-methyl-1-propanamine was added to both sample and reference cuvettes, and spectra were recorded 15 min later. The reduced sample was also treated with CO for 2 min in a gas-tight vial and transferred anaerobically to a sealed cuvette flashed with CO, and spectra were recorded as described above. mutant sGC were washed twice with Dulbecco's PBS and preincubated for 10 min in PBS with 0.5 mM phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine in a 50-l final volume of 10 7 cells per ml. After this, 250 M spermine NONOate or vehicle was added, and the cells were incubated for an additional 5 min at 37°C. The reaction was terminated by the addition of 50 l of 1 M perchloric acid, and cGMP was extracted on ice for 1 h. The extract was centrifuged, neutralized with 2 M K 2 CO 3 , and used for cGMP determination by an RIA (30) . The pellet was dissolved in 0.1 M NaOH and used for a protein assay by the method of Lowry et al. (31) .
Generation of Neuroblastoma Cells Stably Transfected with ␤ Cys-105 .
Neuroblastoma cell line BE2 (American Type Culture Collection) was cultured in DMEM͞F12K medium (GIBCO) supplemented with 10% FBS (Sigma)͞1% penicillin-streptomycin mixture͞1 mM glutamine͞1 mM nonessential amino acids͞1 mM sodium pyruvate. pcDNA-␤ Cys-105 plasmid was transfected by using Lipofectamine reagent (Invitrogen) according to manufacturer protocol. Fortyeight hours posttransfection, 800 g͞ml G418 antibiotic (GIBCO) was added to the culture medium. Two weeks later, individual Neo R colonies were collected by using a 0.5-cm-diameter cloning ring (Corning) and expanded in 100-mm tissue-culture dishes. ␤ Cys-105 -specific 5Ј primer (5Ј-CAGAACCTTGATGCTCTGTGC-3Ј) and pcDNA-specific 3Ј primer (5Ј-CTGATCAGCGGGTTTA-AACGG-3Ј) were used to perform the RT-PCR on mRNA purified from 20 individual Neo R colonies. Three clones with the highest levels of ␤ Cys-105 expression were used for further studies.
Results

Changes in the Heme Content Affect the Basal Activity of the Wild-
Type Enzyme. To test the role of the heme moiety in regulating the basal function of sGC, we investigated the effect of heme removal on the activity of the enzyme. Treatment of the wild-type sGC with increasing concentrations of Tween 20 resulted in the decreased heme content of the enzyme (Fig. 1 ), which correlated with an increase in the basal activity ( Fig. 1) . Reconstitution of the partially heme-depleted sGC with exogenously added hemin not only resulted in the increase of the Soret peak but also decreased the activity of the enzyme (Fig. 1 ). These data suggest that the heme moiety has some inhibitory function in the basal enzyme.
Heme-Deficient ␣␤Cys-105 Mutant sGC Has a High Constitutive Basal
Activity. To test this hypothesis we analyzed the properties of the mutant sGC enzyme carrying a substitution of the His-105 residue of ␤ subunit by a Cys. Mutant enzyme purified to homogeneity ( Fig.  2 Right Inset) was heme-deficient ( Fig. 2 Left Inset) but in the absence of any thiols had a remarkably high basal activity of 7.8 Ϯ 0.2 mol͞mg per min, which is Ϸ70 times higher than the basal activity of the heme-competent wild-type enzyme (Fig. 2) . This basal activity of the mutant was not affected by NO but was somewhat less than 22.1 Ϯ 0.12 mol͞mg per min of activity of NO-stimulated wild-type enzyme (Fig. 2) .
In Vivo Activity of the ␣␤ Cys-105 sGC. To test whether constitutively high basal activity of the mutant enzyme is preserved in vivo, we compared the cGMP accumulation in intact Sf9 cells expressing the ␣␤
Cys-105
mutant or the wild-type enzymes ( Table 1) . As expected, addition of the NO donor spermine NONOate to Sf9 cells expressing wild-type enzyme increased the rate of cGMP accumulation (0.4 Ϯ 0.02 vs. 4.9 Ϯ 0.13 nmol͞mg per 5 min). However, the rate of cGMP accumulation in cells expressing the ␣␤
mutant both before and after spermine NONOate treatment was significantly higher (35 nmol͞mg per min) than the rates observed for cells with wild-type enzyme ( Table 1) .
The human neuroblastoma cell line BE2(C) was reported previously to increase intracellular levels of cGMP after exposure to NO. Our tests indicated that the lysate of these cells posses a specific activity of Ͼ50 pmol͞mg per min (data not shown), which is sufficient to detect sGC activity by measuring directly the conversion of [ mutant is heme-deficient. The addition of hemin to the mutant enzyme decreases the activity of the mutant in a concentration-dependent manner (Fig. 3A) . Conversely, the addition of protoporphyrin IX (PPIX) slightly increased the activity to 10 Ϯ 0.3 mol͞mg per min. The addition of 1 mM DTT to the mutant enzyme significantly inhibited the basal activity (Fig. 3B) . In fact, storage of the mutant enzyme in 5 mM DTT overnight results in an enzyme with a basal activity only 2-to 3-fold higher than the basal activity of the wild-type sGC (28) . DTT and hemin inhibition had an additive effect (Fig. 3B) .
To test whether the mutation affected the properties of the catalytic center of sGC, the K m for Mg 2ϩ -GTP substrate was Values are means Ϯ SD of three measurements. *cGMP levels 48 h postinfection for ␣␤ Cys-105 and 72 h postinfection for ␣␤ sGC.
† 250 M NO donor spermine NONOate was used for intact Sf9 cells and 100 M SNP was used for BE2 lysates. ‡ The activity is at or lower than the detection level for this method. 
measured. We found that the GTP K m for the ␣␤
Cys-105
mutant was Ϸ150 Ϯ 5 M in the presence and 145 Ϯ 9 in the absence of DTT. These values are well within the 65-450 M range of GTP K m measured for various recombinant sGC (15, 26, 32, 33) and are higher than the Ϸ65 and Ϸ50 M GTP K m values determined for the human basal and NO-treated sGC, respectively (15) . This suggests that the high activity of the ␣␤
mutant is not due to changes in catalysis but rather to changes in regulation of sGC activity.
Heme-Reconstituted ␣␤Cys-105 Mutant Regains Ability to Bind and Be
Activated by Gaseous Ligands. Heme-dependent inhibition and partial activation by PPIX of ␣␤ enzyme suggested that the mutant sGC can be reconstituted with heme. The results of the reconstitution experiment are presented in Fig. 4A . Recorded difference spectra indicate that increasing concentrations of heme result in the increased Soret peak. When the reconstituted enzyme was subjected to gel filtration, only a portion of the enzyme (Ϸ60%) retained the heme moiety as judged by change in the OD 280 ͞OD 417 ratio (data not shown). Unlike the Soret peak of the wild-type ferrous sGC (maximum at 431 nm) or oxidized ferric sGC (maximum at 393 nm), the maximum was observed at 417 nm ( Fig. 4B and Table 2 ).
The addition of potassium ferricyanide did not change the spectra and dithionite shifted the Soret peak to 426 nm (Fig. 4) , suggesting that the mutant is reconstituted with a ferric heme; 5 mM DTT has effects similar to dithionate (data not shown).
The ␣␤ Cys-105 enzyme with reduced heme was able to bind CO. After CO treatment, the 426-nm Soret peak shifted to 421 nm (Fig. 4 and Table 2 ), whereas the addition of NO donor DEA-NO resulted in the shift of the spectra toward 398 nm (Fig.  4 and Table 2 ).
Spectral studies of reconstituted mutant correlated well with changes in its catalytic properties. Only the enzyme with reduced heme by at least 1 mM DTT was activated by NO and CO, whereas ␣␤ Cys-105 mutant with ferric heme was not affected (Fig. 5A) . Interestingly, mutant reconstituted with reduced heme was activated to a similar extent by NO or CO (Fig. 5 A and C) , which is different than the wild-type enzyme (10) . Heme reconstitution did not increase the attenuated response of the ␣␤
Cys-105
mutant to BAY41-2272 (Fig. 5B) but restored the additive effect of the allosteric regulator and NO (Fig. 5C ). Values for the ␣␤ Cys-105 mutant are reported. n.u.v., near-UV band; ND, not detected because of the overlapping dithionate absorption but absent when DTT was used (data not shown). results in up to 3-fold activation of the enzyme ( Fig. 1 A and B) , whereas reconstitution of heme inhibits sGC activity ( Fig. 1 C and  D) . This correlation of the heme content with the specific activity (Fig. 1D ) of the heme-depleted͞reconstituted enzyme suggests that the heme moiety of sGC may have an inhibitory function in the basal state of the enzyme. Increase in the activity of the detergenttreated enzyme was also shown in earlier studies in both crude lysates (36) and purified enzyme (35) . All these data suggest that the heme group confines the enzyme in a restricted state.
Discussion
However, removal of the restrictions imposed by the hemecoordinating bond is not sufficient to result in full activation of the enzyme. The presence of PPIX (Fig. 1D and refs. 35 and 37 ) or uncoordinated nitrosyl heme is necessary to provide changes in the regulatory domain, resulting in a fully activated sGC. Thus, it seems that the heme moiety plays a dual role in the function of sGC. In the basal enzyme heme is coordinated with the His-105 residue, which keeps the enzyme in a restricted conformation (Fig. 6) . Removal of the heme by Tween 20 releases the inhibition and produces an enzyme with an ''attenuated'' conformation, which is permissive to the activating effects of the uncoordinated porphyrin moiety of PPIX or nitrosyl heme (Fig. 6A) .
Constitutively Active ␣␤ Cys-105 Enzyme. sGC mutant enzyme with His-105 residue substituted for Cys-105 provides additional evidence supporting the hypothesis described above. Although the Cys residue is known to coordinate heme in many hemoproteins (e.g., cytochrome 450 or NO synthase enzymes), ␣␤
Cys-105
enzyme is heme-deficient (Fig. 2) . In contrast to the previously described ␣␤ , which is only slightly more active than the basal wild-type enzyme (35) , ␣␤ enzyme has a specific activity, which is 70-fold higher than the basal activity of the heme-competent wild-type enzyme and is Ϸ30% of the activity of the NO-activated wild-type sGC (Fig. 2) . Heme-deficient wild-type enzyme is significantly activated by PPIX (Fig. 1D and refs. 35 and 37) , whereas the PPIX effect on NO-activated heme-competent enzyme is marginal. Similarly, ␣␤ , although heme-deficient, is activated only fractionally by PPIX (Fig. 5) effectively competes with the wild-type ␤ subunit to form a heterodimer and displays a high NO-independent constitutive activity.
This activated state of the mutant enzyme is sensitive to treatment with thiols and͞or heme reconstitution. DTT treatment partially inactivated mutant enzyme (Figs. 3-5) , making it receptive to the activation by PPIX and partial activation by BAY41-2272 (Fig. 5B) . It seems that a thiol-dependent interaction(s) within the mutant enzyme mimics the activation effects of PPIX and stabilizes it in an activated conformation (Fig. 6B) . Presumably the thiol environment with DTT present prevents this thiol interaction in the enzyme.
Hemin reconstitution of purified mutant enzyme significantly inactivated ␣␤ Cys-105 enzyme (Fig. 3) , providing additional proof that heme liganding stabilizes the regulatory domain in a restricted conformation, impeding activation of the catalytic center. The DTT-inhibited enzyme was inhibited even further after reconstitution with hemin (Fig. 3B) . Hemin-reconstituted, DTT-treated enzyme displayed not only partial activation by NO or allosteric activation by BAY41-2272 but also demonstrated an additive effect of NO and BAY41-2272 (Fig. 5C ). Wild-type sGC is synergistically activated by NO and BAY41-2272 at low concentrations of NO, but at high NO concentrations, fully activated sGC is affected only modestly by BAY41-2272 (38) . Thus, the mutant enzyme displays properties similar to the wild-type enzyme activated by saturating concentrations of NO. Interestingly, heme-reconstituted mutant enzyme was activated to a similar extent by NO and CO (Fig. 5) . Because the binding of NO and CO to sGC requires reduced ferrous heme, measurements were done in the presence of millimolar DTT. In our experience dithionate inhibits sGC and cannot be used in activity assays (E.M., unpublished observation). Due to the presence of inhibiting DTT, NO and CO could only partially activate the heme-reconstituted mutant enzyme.
UV-Vis spectral analysis of the heme-reconstituted enzyme shed some light on events that are affecting the activity of the enzyme. As summarized in Table 2 , His 3 Cys substitution resulted in spectral characteristics of the mutant enzyme different than the wild-type enzyme, presumably due to the formation of thiolate coordination of heme. Heme oxidation with potassium ferricyanide and reduction with dithionate (Fig. 4) mutant were compared with the properties of cytochrome P450, a model hemoprotein with thiolate-coordinated heme, or its pressure-induced state, known as cytochrome P420. The positions of the Soret maxima of the ferric and ferrous states of heme in the mutant enzyme differ from the characteristics of cytochrome P450 (39) but are almost identical to cytochrome P420. Most indicative is the absence in the CO-treated mutant of the red shift in the Soret band, characteristic for cytochrome P450 (39) . However, the position of the Soret peak after CO treatment is the same as for the pressure-induced cytochrome P420 (Table 2 ). Extensive EPR, magnetic circular dichroism, and Raman spectra analysis of cytochrome P420 demonstrated that, similar to cytochrome P450, the ferric heme is coordinated by the Cys-derived thiolate anion, although with a weakened ironsulfur ligation (increased FeOS stretch) possibly due to protonation of the thiolate anion (40) . This comparison suggests that reconstituted ␣␤ sGC also has a pentacoordinated heme with Cys as the ligand, although with coordination weaker than in cytochrome P450. It should be pointed out that reconstituted ␣␤ sGC also has a prominent shoulder at 360 nm, which increases after storage of reconstituted mutant ␣␤ Cys-105 on ice. Appearance of this shoulder may reflect some transition to a mixed low-and high-spin coordinated heme, similar to thermal shift described for the mutant His-93-Cys myoglobin at Ϫ60°C (41). Alternatively, heme could form a new bond with a different proximal ligand (e.g., adjacent His-107 or Tyr-114), similar to the ligand switch suggested for the CooA transcription factor (42) . Only additional studies will clarify this issue.
It has been suggested that carbonyl heme in cytochrome P420 and His-93-Cys myoglobin is pentacoordinated because of the loss of the weak thiolate coordination (40, 41) . Similar assumptions can be made about the ␣␤ sGC. In this respect CO-induced loss of heme coordination is similar to the effects of NO. Consequently, ␣␤ mutant is equally stimulated by NO and CO (Fig. 5 A  and C) .
In summary, our data suggest that the heme prosthetic group of sGC maintains the enzyme in a basal state with the regulatory domain of sGC in an inhibited restricted conformation through its coordination with an axial residue (Fig. 6) . Disruption of the coordination and removal of this inhibition permits the transition of the enzyme to an activated state due to the activating role of the porphyrin moiety of nitrosylated heme. Substitution of coordinating His-105 with Cys and the resulting heme deficiency favor the transition of the sGC regulatory domain into an activated conformation. This transition is facilitated or stabilized by some thioldependent interaction. Mutant sGC enzyme can be maintained in an activated state without heme and stimulatory ligands, such as NO or allosteric regulators. The constitutively active mutant could be a useful reagent to screen for novel inhibitors and activators of sGC or to analyze cGMP-dependent effects on cellular physiology. Gene delivery of the mutant ␣␤
sGC could also be beneficial in disorders for which increased cGMP levels are desired.
